NCT00058474 · CITED IN SOURCE DOCUMENTS

Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE3
Status at capture: UNKNOWN
Registry last update: 2016-03-23

RATIONALE: Drugs used in chemotherapy, such as capecitabine, fluorouracil, and oxaliplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: This randomized phase III trial is studying radiation therapy and either capecitabine or fluorouracil with or without oxaliplatin and comparing them to see how well they work when given before surgery in treating patients with resectable rectal cancer. It is not yet known whether radiation therapy and either capecitabine or fluorouracil is more effective with or without oxaliplatin in treating rectal cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients must consent to participate in the study and must have signed and dated an IRB-approved consent form conforming to federal and institutional guidelines. * Patients must be \> 18 years of age. * Patients must have a life expectancy of 5 years, excluding their diagnosis of cancer (as determined by the investigator), and must have an Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0 or 1. * Patients must have a diagnosis of adenocarcinoma of the rectum obtained by a biopsy technique which leaves the major portion of the tumor intact. * The interval between the initial diagnosis of rectal adenocarcinoma and randomization must be no more than 42 days. * Prior to randomization, the investigator must specify the intent for sphincter saving or non-sphincter saving surgery. * The tumor must be either palpable by digital rectal exam or be accessible via a proctoscope or sigmoidoscope. * Distal border of the tumor must be located \< 12 cm from the anal verge. * The tumor must be considered by the surgeon to be amenable to curative resection. (Note that curative resection can include pelvic exenteration.) * The tumor must be clinically Stage II (T3-4 N0 with N0 being defined as all imaged lymph nodes are \< 1.0 cm) or Stage III (T1-4 N1-2 with the definition of a clinically positive node being any node \> 1.0 cm). Stage of the primary tumor may be determined by ultrasound or Magnetic Resonance Imaging (MRI). Computed Tomography (CT) scan is acceptable provided there is evidence of T4 and/or N1-2 disease. * At the time of randomization, all patients must have had the following within the previous 42 days: history and physical examination; if technically feasible, a complete colonoscopic examination; if not feasible, a proctoscopic or sigmoidoscopic exam; clinical staging of the tumor; CT or MRI of the abdomen and pelvis (combined PET/CT may be substituted), and a chest x-ray (PA and lateral) or CT scan of the chest to exclude patients with metastatic disease. * At the time of randomization: Absolute neutrophil count (ANC) must be \> 1,200/mm3; Platelet count must be \> 100,000/mm3; There must be evidence of adequate hepatic function as follows: total bilirubin must be \< 1.5 x the upper limit of normal (ULN) for the lab; and alkaline phosphatase must be \< 2.5 x Upper Limit of Normal (ULN) for the lab; and the Aspartate Amino Transferase (AST) must be \< 2.5 x ULN for the lab; and If AST is \> ULN, serologic testing for Hepatitis B and C must be performed and results must be negative; Calculated creatinine clearance must be \> 50 mL/min. * Patients with prior malignancies, including invasive colon cancer, are eligible if they have been disease-free for \> 5 years and are deemed by their physician to be at low risk for recurrence. Patients with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are eligible, even if these conditions were diagnosed within 5 years prior to randomization. Exclusion Criteria: * Findings of metastatic disease. * On imaging, clear indication of involvement of the pelvic side wall(s). * Rectal cancers other than adenocarcinoma, i.e., sarcoma, lymphoma, carcinoid, squamous cell carcinoma, cloacogenic carcinoma, etc. * History of invasive rectal malignancy, regardless of disease-free interval. * Pregnancy or lactation at the time of proposed randomization. Eligible patients of reproductive potential (both sexes) must agree to use adequate contraceptive methods. * Any therapy for this cancer prior to randomization. * Synchronous colon cancer. * History of viral hepatitis or other chronic liver disease. * Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude the patient from receiving any chemotherapy treatment option or would prevent required follow-up. Specifically excluded are patients with active ischemic heart disease (class III\* or class IV\*\* myocardial disease as described by the New York Heart Association), a recent history (within 6 months) of myocardial infarction, or symptomatic arrhythmia at the time of randomization. \*Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Such patients are comfortable at rest. Less than ordinary physical activity that causes fatigue, palpitation, dyspnea, or anginal pain. \*\*Class IV: Patients with cardiac disease resulting in inability to perform any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. * Patients who, in the opinion of the investigator, have uncontrolled hypertension. * Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic). * Prior pelvic radiation therapy for any reason. * Known hypersensitivity to 5-fluorouracil, capecitabine, or oxaliplatin. * Clinically significant peripheral neuropathy at the time of randomization (defined in the NCI Common Terminology Criteria for Adverse Events Version 3.0 \[CTCAE v3.0\] as grade 2 or greater neurosensory or neuromotor toxicity). * Existing uncontrolled coagulopathy. * Inability to take oral medications. * Participation in any investigational drug study within 4 weeks prior to randomization. * Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
intervention Names
Drug: fluorouracil
Radiation: radiation therapy
label
Arm 1: 5-FU + RT
type
ACTIVE_COMPARATOR
description
Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
intervention Names
Drug: fluorouracil
Drug: oxaliplatin
Radiation: radiation therapy
label
Arm 2: 5-FU + RT + Oxaliplatin
type
EXPERIMENTAL
description
Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
intervention Names
Drug: capecitabine
Radiation: radiation therapy
label
Arm 3: Capecitabine + RT
type
EXPERIMENTAL
description
Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
intervention Names
Drug: capecitabine
Drug: oxaliplatin
Radiation: radiation therapy
label
Arm 4: Capecitabine + RT + Oxaliplatin
type
EXPERIMENTAL

interventions

arm Group Labels
Arm 3: Capecitabine + RT
Arm 4: Capecitabine + RT + Oxaliplatin
description
825 mg/m2 oral daily 5 days a week on days of planned RT
name
capecitabine
type
DRUG
arm Group Labels
Arm 1: 5-FU + RT
Arm 2: 5-FU + RT + Oxaliplatin
description
225 mg/m2 IV daily continuous infusion
name
fluorouracil
other Names
5-FU
type
DRUG
arm Group Labels
Arm 2: 5-FU + RT + Oxaliplatin
Arm 4: Capecitabine + RT + Oxaliplatin
description
50 mg/m2 IV 5 days a week on days of planned RT
name
oxaliplatin
type
DRUG
arm Group Labels
Arm 1: 5-FU + RT
Arm 2: 5-FU + RT + Oxaliplatin
Arm 3: Capecitabine + RT
Arm 4: Capecitabine + RT + Oxaliplatin
description
Given 5 days a week for 5-6 weeks
name
radiation therapy
other Names
RT
type
RADIATION

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 1608
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

measure
Loco-regional disease control as assessed by evidence of tumor at 3 years
time Frame
Time from randomization to first local recurrence up to 3 years

secondary Outcomes

measure
Clinical complete response as assessed by digital rectal exam and sigmoidoscopy or proctoscopy at time of definitive analysis
time Frame
Prior to surgery approximately 6 weeks
measure
Pathologic complete response as assessed by gross and microscopic exam of surgical specimens at time of definitive analysis
time Frame
At the time of surgery approximately 6 weeks
measure
Sphincter-saving surgery at time of definitive analysis
time Frame
At the time of surgery approximately 6 weeks
measure
Survival as measured by deaths from any cause at time of definitive analysis
time Frame
From time of randomization through 5 years
measure
Disease-free survival as assessed by recurrence, second primary cancer, or death from any cause at time of definitive analysis
time Frame
From time of randomization through 5 years
measure
Tissue biomarkers as assessed by analysis of tumor tissue using current biotechnology after definitive analysis
time Frame
At the time of surgery approximately 6 weeks
measure
Quality of life as assessed by FACT-C trial outcome index and EORTC CR38 after definitive analysis
time Frame
Assessed prior to therapy and at approximately 5 weeks, 15 months, 5 years
measure
Neurotoxicity as assessed by FACT-NTX scale after definitive analysis
time Frame
Assessed prior to therapy and at approximately 5 weeks, 15 months, 5 years
measure
Symptoms as assessed by fluoropyrimidine symptom scale adapted from SWOG after definitive analysis
time Frame
Assessed prior to therapy and at approximately 5 weeks, 15 months
measure
Vitality as assessed by SF-36 vitality scale after definitive analysis
time Frame
Assessed prior to therapy and at approximately 5 weeks, 15 months, 5 years
measure
Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis
time Frame
Assessed prior to therapy and at approximately 5 weeks, 15 months

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy, such as capecitabine, fluorouracil, and oxaliplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: This randomized phase III trial is studying radiation therapy and either capecitabine or fluorouracil with or without oxaliplatin and comparing them to see how well they work when given before surgery in treating patients with resectable rectal cancer. It is not yet known whether radiation therapy and either capecitabine or fluorouracil is more effective with or without oxaliplatin in treating rectal cancer.
detailed Description: OBJECTIVES: Primary * Compare the rate of local-regional relapse in patients with resectable rectal cancer treated with chemoradiotherapy comprising radiation therapy and either capecitabine or fluorouracil with or without oxaliplatin. Secondary * Compare the rate of clinical complete response in patients treated with these regimens. * Compare the rate of pathologic complete response in patients treated with these regimens. * Determine the increase in the number of patients who are able to undergo sphincter-saving surgery after treatment with these regimens. * Correlate genetic patterns and the presence or absence of specific tissue biomarkers with response and prognosis in patients treated with these regimens. * Compare preoperative quality of life (QOL) of patients treated with oral capecitabine versus continuous infusion with fluorouracil. * Determine the impact of oxaliplatin on neurotoxicity in patients treated with these regimens. * Compare the toxic effects of these regimens in these patients. * Compare the convenience of care in patients treated with these regimens. * Determine the impact of the type of surgical management on QOL at 1 and 5 years postoperatively in these patients. * Describe the long-term impact of cancer treatment on symptoms (e.g., vitality and neurotoxicity) and QOL at 5 years after randomization (5-year follow-up visit). OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, gender, clinical tumor stage (stage II vs stage III), and surgical intent (sphincter saving vs non-sphincter saving). Patients are randomized to 1 of 4 treatment arms. * Arm 1: Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks. * Arm 2: Patients receive fluorouracil and undergo radiotherapy as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks. * Arm 3: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily 5 days a week for 5-6 weeks. * Arm 4: Patients receive capecitabine and undergo radiotherapy as in arm 3. Patients also receive oxaliplatin as in arm 2. Within 6-8 weeks after the completion of chemoradiotherapy, patients with responding or stable disease undergo surgery. Patients with progressive disease are treated at the discretion of the investigator and continue to be followed. Quality of life is assessed at baseline, at completion of chemoradiotherapy, and at 1 and 5 years after surgery. After completion of study treatment, patients are followed every 6 months for 5 years. PROJECTED ACCRUAL: A total of 1,606 patients will be accrued for this study within 4 years.

Source references

references

citation
Ganz PA, Lopa SH, Yothers G, et al.: Comparative effectiveness of sphincter-sparing surgery (SSS) versus abdomino-perineal resection (APR) in rectal cancer: patient-reported outcomes (PROs) from NSABP R-04. [Abstract] J Clin Oncol 30 (Suppl 15): A-3545, 2012.
type
RESULT
citation
Roh MS, Yothers GA, O'Connell MJ, et al.: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. [Abstract] J Clin Oncol 29 (Suppl 15): A-3503, 2011.
type
RESULT
citation
O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5.
pmid
24799484
type
RESULT
citation
Russell MM, Ganz PA, Lopa S, Yothers G, Ko CY, Arora A, Atkins JN, Bahary N, Soori GS, Robertson JM, Eakle J, Marchello BT, Wozniak TF, Beart RW Jr, Wolmark N. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Ann Surg. 2015 Jan;261(1):144-8. doi: 10.1097/SLA.0000000000000594.
pmid
24670844
type
RESULT
citation
Peipert JD, Roydhouse J, Tighiouart M, Henry NL, Kim S, Hays RD, Rogatko A, Yothers G, Ganz PA. Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04. Qual Life Res. 2024 Nov;33(11):3069-3079. doi: 10.1007/s11136-024-03746-5. Epub 2024 Jul 30.
pmid
39080091
type
DERIVED
citation
Ganz PA, Hays RD, Spritzer KL, Rogatko A, Ko CY, Colangelo LH, Arora A, Hopkins JO, Evans TL, Yothers G. Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R-04. Cancer. 2022 Sep 1;128(17):3233-3242. doi: 10.1002/cncr.34341. Epub 2022 Jun 24.
pmid
35749631
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-1c155ad0ece64296d80e
requested nct id
NCT00058474
primary nct id
NCT00058474
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/colorectal/hp/rectal-treatment-pdq
source record id
Source null
source file sha256
a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
payload sha256
496f68fd89536a908dec5162ae03dfbb6c1c0a285707ef7b7276dad7fb50a7f9
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-1c155ad0ece64296d80e
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT00058474
occurrences
context exact
liplatin (24% vs. 8%; <em>P</em> <.001). Longer-term outcomes including OS have not yet been reported.</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00058474">NSABP-R-04</a> trial (NCT00058474) randomly assigned 1,608 patients with clinically staged T3 or T4 or clinical node-positive adenocarcinoma within 12 cm of
end
216803
exact text
NCT00058474
start
216792
context exact
t;.001). Longer-term outcomes including OS have not yet been reported.</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00058474">NSABP-R-04</a> trial (NCT00058474) randomly assigned 1,608 patients with clinically staged T3 or T4 or clinical node-positive adenocarcinoma within 12 cm of the anal verge in a 2 × 2 fact
end
216838
exact text
NCT00058474
start
216827
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
source file sha256
a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:21:38.943216+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
source title
Rectal Cancer Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: February 12, 2025
datetime
2025-02-12T12:00:00Z
display
February 12, 2025
source url
https://www.cancer.gov/types/colorectal/hp/rectal-treatment-pdq

Preserved source evidence · Independent clinical review pending · Not medical advice